Abstracts Archive - Page 269 of 2607 - ACR Meeting Abstracts

Abstract Number: 0390 • ACR Convergence 2024
Treatment Effectiveness Following Switching from Initial TNF Inhibitor in Juvenile Idiopathic Arthritis
Mei-Sing Ong¹, Sarah Ringold², Melissa Mannion³, Marc Natter⁴ and Yukiko Kimura⁵, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ²Washington University, Seattle, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Boston Children's Hospital, Boston, MA, ⁵Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Although the increasing availability of biologic therapies has significantly improved outcomes for patients with JIA, a substantial proportion of patients require switching from the…
Abstract Number: 0593 • ACR Convergence 2024
Value of the Routine Assessment of Patient Index Data 3 in Assessing Disease Severity and Treatment Effect in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast
Alvin F. Wells¹, Arthur Kavanaugh², William Tillett³, Philip S. Helliwell⁴, Marijn Vis⁵, Yuri Klyachkin⁶, Cynthia Deignan⁷, Lichen Teng⁷, Rebecca Wang⁷ and Alexis Ogdie⁸, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University of California San Diego, La Jolla, CA, ³Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁵Erasmus MC, Rotterdam, Netherlands, ⁶Amgen, Lexington, KY, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) score is a composite of 3 patient-reported outcomes (PROs): Health Assessment Questionnaire (HAQ), pain visual…
Abstract Number: 0603 • ACR Convergence 2024
Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry
Jakub Závada¹, Jana Baranová², Karel Pavelka¹, Jiří Vencovský³, Pavel Horak⁴, Kateřina Kusalová² and Ladislav Šenolt³, and collaborators of the ATTRA registry, ¹Institute of Rheumatology and Charles University, Praha, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic
Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
Abstract Number: 0610 • ACR Convergence 2024
Clinical Evaluation on IFI44L Gene Methylation Detection for Diagnosis of Systemic Lupus Erythematosus by Methylation Sensitive High Resolution Melting (MS-HRM)
Xiaoping hong and liancheng lin, The Second Clinical Medical College of Jinan University, Shenzhen, China (People's Republic)
Background/Purpose: To evaluate the clinical effectiveness of IFI44L gene methylation detection for the diagnosis of Systemic Lupus Erythematosus (SLE) by MS-HRM, to determine the relative…
Abstract Number: 0600 • ACR Convergence 2024
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies
Laure Gossec¹, Dafna Gladman², Laura Coates³, Maarten de Wit⁴, Barbara Ink⁵, Rajan Bajracharya⁵, Jason Coarse⁶, Jérémy Lambert⁷ and Ana-Maria Orbai⁸, ¹Sorbonne Université, Paris, France, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ⁴Stichting Tools, Patient Research Partner, Amsterdam, Netherlands, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Morrisville, NC, ⁷UCB Pharma, Colombes, France, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL‑17F in addition to IL‑17A, has demonstrated sustained reductions in disease impact of PsA, assessed…
Abstract Number: 0574 • ACR Convergence 2024
14-3-3 Eta (η) Auto-Antibody as a Diagnostic Marker in Axial Spondyloarthritis: A Longitudinal Study
Anthony Marotta¹, Walter Maksymowych², Stephanie Wichuk² and Navneet Sidhu¹, ¹Augurex Life Sciences Corp, Vancouver, BC, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Diagnosis of axial spondyloarthritis (AxSpA) is challenging and often delayed primarily due to the lack of sensitive and specific markers needed for accurate and…
Abstract Number: 0602 • ACR Convergence 2024
Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration
Joseph F. Merola¹, Philip Mease², Atul Deodhar³, Alice Gottlieb⁴, Barbara Ink⁵, Dirk de Cuyper⁶, Rajan Bajracharya⁵, Jérémy Lambert⁷, Jason Coarse⁸ and Laura Coates⁹, ¹UT Southwestern Medical Center, Dallas, TX, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Morrisville, NC, ⁹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom
Background/Purpose: The Group for Research and Assessment of Psoriasis and PsA (GRAPPA) domain‑based treatment recommendations for PsA focus on six key domains: peripheral arthritis, axial…
Abstract Number: 0586 • ACR Convergence 2024
Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
Alexis Ogdie¹, Xiaolan Ye², Yi Peng³, Christopher Saffore⁴, Jayne Stigler⁵ and Martin Bergman⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie Inc., waukegan, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶self, Beach Haven, NJ

Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated efficacy for the treatment of PsA in randomized controlled trials of patients with inadequate response or…
Abstract Number: 0573 • ACR Convergence 2024
Characteristics of Difficult-to-Treat Ankylosing Spondylitis- Results from Real-World Data
Ansaam Daoud¹, Jennifer Murphy², Omer Pamuk³ and Marina Magrey⁴, ¹Case Western Reserve University/University Hospitals, Akron, OH, ²University Hospitals, Cleveland, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ⁴Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: A large proportion of patients with ankylosing spondylitis (AS) are considered difficult to treat (D2T).The study aimed to compare baseline characteristics, extra-articular manifestations (EAM),…
Abstract Number: 0503 • ACR Convergence 2024
Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations
Patrick-Pascal Strunz¹, Linus Maximilian Risser², Matthias Englbrecht³, Torsten Witte⁴, Matthias Froehlich⁵, Marc Schmalzing⁶, Michael Gernert⁷, Peter Bartz-Bazzanella⁸, Sebastian Hueper⁹, Cay von Der Decken¹⁰, Georg Gauler¹¹, Susanna Spaethling-Mestekemper¹², Christoph Kuhn¹³, Kirsten Karberg¹⁴, Wolfgang Vorbrueggen¹⁵, Martin Welcker¹⁶ and Stefan Kleinert¹⁷, ¹University hospital of Wuerzburg, Wuerzburg, Germany, ²Hannover Medical School, Hannover, Germany, ³Freelance Healthcare Data Scientist, Eckental, ⁴Dept of Immunology and Rheumatology, Hannover, Germany, ⁵Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, ⁶University Hospital Wuerzburg, Würzburg, Germany, ⁷Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, ⁸Rhein-Maas Klinikum, Wuerselen, Germany, ⁹Praxis für Rheumatologie und Osteologie, Hildesheim, Germany, ¹⁰Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, ¹¹rheumapraxis, Osnabrück, Germany, ¹²Rheumapraxis Muenchen, Muenchen, Germany, ¹³Praxis für Rheumatologie, Karlsruhe, Germany, ¹⁴Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, ¹⁵RheumaDatenRhePort GbR, Wuerselen, Germany, ¹⁶Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ¹⁷Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany
Background/Purpose: Safety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence prescription patterns for drugs used…
Abstract Number: 0582 • ACR Convergence 2024
Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with clinically meaningful improvements in disease activity and patient (pt)-reported outcomes among pts with PsA.1 However, it is…
Abstract Number: 0613 • ACR Convergence 2024
Prediction of Spontaneous Abortion in Women with Systemic Lupus Erythematosus (SLE) Based on Machine Learning Model: Insights from the Egyptian College of Rheumatology (ECR)–SLE Cohort
Nevin Hammam¹, Walaa N. Ismail², Iman I EL-Gazzar³, Osman Hammam⁴, Noha M Khalil⁵, Eman F Mohamed⁶, Nermeen Noshy⁷, Dina F El-Essawi⁸, Rawhya R El Shereef⁹, Faten Ismail⁹, Marwa ElKhalifa¹⁰, Hanan M Fathi¹¹, Soha Senara¹¹, Samar Tharwat¹², Samah I Nasef¹³, Amany R El-Najjar¹⁴, Ahmed M Abdalla¹⁵, Ali Bakhiet¹⁶, Ahmed Elsaman¹⁷ and Tamer A Gheita³, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Boston, MA, ²Faculty of Computers and Information, Minia University, Minia;, Minia, Egypt, ³Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ⁴Department of Rheumatology and Rehabilitation, Faculty of Medicine, New Valley University, New Valley, Assiut, Egypt, ⁵Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, ⁶Internal Medicine Department, Rheumatology Unit, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt, ⁷Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Ain-Shams University, Cairo, Egypt, ⁸Internal Medicine Department, Rheumatology Unit, Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, ¹⁰Alexandria faculty of Medicine, Alexandria, Egypt, ¹¹Rheumatology Department, Faculty of Medicine, Fayoum University,, Fayoum, Egypt, ¹²Rheumatology Unit, Internal Medicine, Mansoura University, Dakahlia, ¹³Rheumatology Department, Faculty of Medicine, Suez-Canal University, Ismailia, Egypt, ¹⁴Rheumatology Department, Faculty of Medicine, Zagazig University, Sharkia, Egypt, ¹⁵Rheumatology Department, Faculty of Medicine, Aswan University, Aswan, Egypt, ¹⁶Higher institute of Computer Science and Information Systems, Culture & Science City, Giza, Egypt, ¹⁷Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects women of childbearing period. SLE increases the risk of adverse pregnancy outcome including spontaneous abortion (SA), which causes emotional stress to…
Abstract Number: 0555 • ACR Convergence 2024
The Effect of Alcohol Consumption on Clinical Outcomes and Structural Damage in Patients with Axial Spondyloarthritis: A Systematic Literature Review and Meta-Analysis
Sinead Maguire¹, Nigil Haroon², Robert Inman³, Melanie Anderson⁴, Evelyne Gendron⁵ and Sindhu R. Johnson⁶, ¹University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Toronto, Canada, ²Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Quebec City, QC, Canada, ⁶University of Toronto, Toronto, Canada
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic progressive inflammatory disease characterized by the involvement of the axial skeleton. Alcohol consumption (AC) is a modifiable lifestyle…
Abstract Number: 0431 • ACR Convergence 2024
Reproductive Health in Women with Rheumatic Diseases: Knowledge and Behaviors
Abraham Yair Lujano-Negrete¹, Lorena Perez-Barbosa², Conrado Garcia³, CASSANDRA SKINNER TAYLOR⁴, Jose Hernandez Linas³, Adriana Lobato-Belmonte³, Yesenia Ambriz Murillo⁵, Alfonso Gastelum-Strozzi⁶, Amaranta Manrique de Lara⁷, Ana Rodriguez-Flores⁸, Jesus Cardenas-de la Garza⁹, Marco Maradiaga-Cecena¹⁰, Galilea Rodriguez Orozco¹¹, Anahí Carrazco Chapa¹¹, Dionicio Galarza-Delgado¹² and Ingris del Pilar Pelaez Ballestas³, and Grupo de estudio de salud reproductiva en enfermedades reumáticas autoinmunes en Mexico, ¹Hospital Universitario Jose Eleuterio Gonzalez, UANL, Internal Medicine, Monterrey, Mexico, Monterrey, Mexico, ²Hospital Universitario, UANL, Monterrey, Mexico, ³Hospital General de Mexico Dr. Eduardo Liceaga, Rheumatology, Mexico City, Mexico, Mexico, Mexico, ⁴HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, ⁵Hospital Regional de Morelia, Rheumatology, Morelia, Mexico, Morelia, Mexico, ⁶Instituto de Ciencias Aplicadas y Tecnología, UNAM, Mexico City, Mexico, Monterrey, Mexico, ⁷Hospital General de Mexico Dr. Eduardo Liceaga, Rheumatology, Mexico City, Mexico, Mexico City, Mexico, ⁸Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁹Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ¹⁰Hospital General de Culiacan, Rheumatology, Culiacan, Mexico, Culiacan, Sinaloa, Mexico, ¹¹Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, ¹²UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARDs) affect women during their childbearing years, often leading to pregnancy complications. Effective management of this population requires family planning and…
Abstract Number: 0423 • ACR Convergence 2024
Higher Risk of Preterm Delivery in Women with Rheumatoid Arthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys
Sabrina Hamroun¹, Grégoire Martin De Frémont², Nathalie Costedoat-chalumeau³, Marion couderc⁴, René-Marc Flipo⁵, Laure Gossec⁶, Christophe Richez⁷, Rakiba Belkhir⁸, Aline Frazier⁹, Valerie Devauchelle¹⁰, Hubert Marotte¹¹, Jérémie Sellam¹², Elisabeth Gervais¹³, Alban Deroux¹⁴, Cedric Lukas¹⁵, Emmanuelle Dernis¹⁶, Emmanuel Chatelus¹⁷, Véronique Le Guern¹⁸, Gaëlle Guettrot-Imbert¹⁹, Nathalie Lelong²⁰, Camille Le Ray²⁰, Raphaele Seror²¹ and Anna Molto²², and ENP 2021 and GR2 Study Groups, ¹Cochin University Hospital, Paris, Ile-de-France, France, ²Le Kremlin-Bicêtre University Hospital, Le Kremlin-Bicêtre, Guyana, ³University Paris Cité, Paris, France, ⁴CHU de Clermont-Ferrand, Clermont-Ferrand, ⁵CHU Lille, Lille, Nord-Pas-de-Calais, France, ⁶Sorbonne Université, Paris, France, ⁷Pellegrin Hospital, Rheumatology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Bordeaux, France, ⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, ⁹Lariboisière University Hospital, Paris, France, ¹⁰UBO, Brest, France, ¹¹Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, ¹²Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France, ¹³University hospital, Poitiers, France, ¹⁴Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ¹⁵Rheumatology department, CHU Montpellier, Montpellier, France, ¹⁶CH LE MANS, LE MANS, Pays de la Loire, France, ¹⁷Rheumatology department strasbourg, Strasbourg, France, ¹⁸APHP, Hôpital Cochin, Paris, ¹⁹Cochin Hospital, Paris, France, ²⁰University of Paris, INSERM Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Paris, France, ²¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ²²Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) regularly affects women of childbearing age1. A higher obstetric morbidity in women with RA is suggested in the literature in several…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].